GRAIL, Inc.

GRAL

US3847471014

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-12 pm EST			5-day change	1st Jan Change
105.93 ^USD	+5.82%		+10.63%	+23.76%

Jan. 12	GRAIL, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
Dec. 05	Grail Insider Sold Shares Worth $2,478,818, According to a Recent SEC Filing	MT

GRAIL, Inc. announced that it has received $324.999987 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd., Samsung C&T Corporation

Published on 11/06/2025

S&P Capital IQ

GRAIL, Inc.

+5.82%

Samsung Electronics Co., Ltd.

+0.14%

Samsung C&T Corporation

-0.74%

On November 7, 2025, GRAIL, Inc closed the transaction. The transaction included participation from 17 investors.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
GRAIL, INC.	105.93USD	+5.82%	+10.63%	3.9B
SAMSUNG ELECTRONICS CO., LTD.	139,000.00KRW	+0.14%	+8.17%	623B
SAMSUNG C&T CORPORATION	268,500.00KRW	-0.74%	+9.59%	29.98B

Latest news about GRAIL, Inc.

Jan. 12	GRAIL, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
Dec. 05	Grail Insider Sold Shares Worth $2,478,818, According to a Recent SEC Filing	MT
Dec. 05	Grail Insider Sold Shares Worth $3,809,535, According to a Recent SEC Filing	MT
Dec. 05	Grail Insider Sold Shares Worth $1,300,000, According to a Recent SEC Filing	MT
Dec. 02	Morgan Stanley Raises Price Target on GRAIL to $110 From $85, Keeps Equalweight Rating	MT
Nov. 14	Grail Enters $300 Million Equity Distribution Agreement	MT
Nov. 14	Grail Inc may offer common stock up to $300 million - SEC filing	RE
Nov. 13	GRAIL, Inc. - Analyst/Investor Day
Nov. 12	GRAIL, Inc., Q3 2025 Earnings Call, Nov 12, 2025
Nov. 12	GRAIL Q3 Loss Narrows, Revenue Rises	MT
Nov. 12	Earnings Flash (GRAL) GRAIL Posts Q3 Loss $2.46	MT
Nov. 12	Earnings Flash (GRAL) GRAIL, Inc. Reports Q3 Revenue $36.2M, vs. FactSet Est of $34.6M	MT
Nov. 12	GRAIL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 12	GRAIL Shares Rise After Guggenheim Upgrade	MT
Nov. 12	Guggenheim Upgrades GRAIL to Buy From Neutral, Price Target is $100	MT
Nov. 06	GRAIL, Inc. announced that it has received $324.999987 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd., Samsung C&T Corporation	CI
Nov. 03	Manulife to Offer Galleri Multi-Cancer Early Detection Test	MT
Nov. 03	Manulife Brief: Says First Canadian Insurer to Offer the Galleri Multi-Cancer Early Detection Test by GRAIL	MT
25-10-20	GRAIL, Inc. - Special Call
25-10-20	Grail, University of Oxford Unveil Data From Multi-Cancer Early Detection Study	MT
25-10-20	Grail, Inc. and University of Oxford to Present Long-Term Data from the Symplify Study Evaluating the Galleri®? Multi-Cancer Early Detection Test in Symptomatic Individuals At the Early Detection of Cancer Conference	CI
25-10-18	GRAIL, Inc. Announces Positive Performance and Safety Results from its Registrational Pathfind 2 Study	CI
25-10-17	South Korean Shares Close Flat Amid Possible Trade Deal with US	MT
25-10-16	Samsung Electronics, Samsung C&T to Invest $110 Million in US-based Biotechnology Firm Grail	MT
25-10-16	Sector Update: Health Care Stocks Softer Late Afternoon	MT

GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

Employees

1,000

Sector

Biotechnology & Medical Research

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company